Charles River Laboratories International, Inc. (NYSE:CRL) announced
today the appointment of John Crowley to the role of Corporate Senior
Vice President, Corporate Controller and Chief Accounting Officer,
effective September 30. In this newly created position, Mr.
Crowley will be responsible for providing strategic guidance to the
finance groups, including directing the corporate accounting function
and practices, maintaining its fiscal records and preparing its
financial reports. He will also oversee the design and operation of the
Charles River’s system of internal controls, ensuring compliance with
the rules and regulations of the Sarbanes-Oxley Act.
Immediately prior to joining Charles River, Mr. Crowley was Vice
President, Chief Accounting Officer & Corporate Controller of Ironwood
Pharmaceuticals. Previously, he held senior corporate finance positions
at Vertex Pharmaceuticals where he successfully managed and directed all
areas of technical accounting.
James C. Foster, Chairman, President, and Chief Executive Officer of
Charles River Laboratories, commented, “John brings a wealth of
financial acumen to Charles River. His expertise and experience in the
life sciences industry is a welcomed addition to our executive team.”
Mr. Crowley commented, “Charles River has a compelling value proposition
and a unique business model. I look forward to playing an integral role
in its future growth and success.”
Mr. Crowley holds a B.S. in both Economics and Accountancy from Babson
College and is a certified public accountant.
Caution Concerning Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words such as
“anticipate,” “believe,” “expect,” “will,” “may,” “estimate,” “plan,”
“outlook,” and “project” and other similar expressions that predict or
indicate future events or trends or that are not statements of
historical matters. Forward-looking statements are based on Charles
River’s current expectations and beliefs, and involve a number of risks
and uncertainties that are difficult to predict and that could cause
actual results to differ materially from those stated or implied by the
forward-looking statements. A description of these risks, uncertainties,
and other matters can be found in the Risk Factors detailed in Charles
River's Annual Report on Form 10-K as filed on February 27, 2013, as
well as other filings we make with the Securities and Exchange
Commission. Because forward-looking statements involve risks and
uncertainties, actual results and events may differ materially from
results and events currently expected by Charles River, and Charles
River assumes no obligation and expressly disclaims any duty to update
information contained in this news release except as required by law.
About Charles River Laboratories
Accelerating Drug Development. Exactly. Charles River provides essential
products and services to help pharmaceutical and biotechnology
companies, government agencies and leading academic institutions around
the globe accelerate their research and drug development efforts. Our
dedicated employees are focused on providing clients with exactly what
they need to improve and expedite the discovery, early-stage development
and safe manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services, visit www.criver.com
Copyright Business Wire 2013